The funds raised through these transactions will be used to reduce promoter leverage by up to Rs100cr and which will subsequently bring down the Promoters pledged position to around 30% from current level of 54%. This is in line with their commitment given during Q3FY19 earnings call to reduce the pledge continuously and make it pledge free within two years. The promoters also reduced some amount of their personal loan in the month of December 2018, which enabled the reduction from their highest point of the pledge of 60% to the current level of 54%.
This step has been taken after due consultation with all sets of stakeholders, and to address the concerns related to promoter pledge.
The promoters would also like to strongly reiterate their conviction in the company's future prospects. Granules India has started its growth momentum from the current financial year, having witnessed 3 consecutive strong quarters with high double-digit growth in profits, and is among the very few integrated pharmaceutical companies in India and fully FDA compliant. The management is confident and aspires to continue to meet and exceed all the Company’s stated goals.
Granules India Ltd is currently trading at Rs111.40 up by Rs7.6 or 7.32% from its previous closing of Rs103.80 on the BSE. The scrip opened at Rs104 and has touched a high and low of Rs114.30 and Rs101 respectively.